University of Missouri
Columbia, Missouri, 65212, United States
NCT Number: NCT03683589
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese subjects with low IHTG. The purpose of this study is to directly by measure DNL in human liver tissue and comparing it to liver histological scores from patient biopsies.
Looking for future studies?
Notify Me22 year–65 year
All sexes
Observational
Columbia, Missouri, 65212, United States
The development of nonalcoholic fatty liver disease (NAFLD) progresses from a state of elevated intrahepatic triglycerides (IHTG) to liver inflammation, and ultimately, hepatic apoptosis and fibrosis. NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese participants with low IHTG. DNL is the process of liver synthesis of fatty acids (FAs) from carbohydrate. In humans, studies have shown that DNL significantly predicts the magnitude of IHTG, however, it is unknown whether the pathway plays a role in disease progression. Evidence supporting this concept includes the fact that the primary product of DNL is the saturated FA, palmitate, which in cell culture has been shown to significantly contribute to oxidative stress and inflammation. Recent rodent data show that upregulation of DNL through dietary supplementation of sucrose exacerbated the hepatotoxic effects of excess dietary FAs. A preliminary abstract presented by others at the 2017 Liver Meeting suggested that DNL may not be different between patients with low and high liver fibrosis, although these data were collected using an indirect measure of liver disease. Here, in the present study, the hypothesis will be tested directly by measuring DNL in human liver tissue and comparing it to liver histological scores (NAFLD Activity Score, NAS) from patient samples.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion and exclusion criteria are similar to the criteria set by a larger project (NCT03151798).
Inclusion criteria
Exclusion criteria
Time frame: Dec 2019
DNL will be measured directly in the liver biopsies
Time frame: Dec 2019
Tissue histology will be performed to obtain NAFLD activity score (NAS). A pathologist, trained in determining the NAS of histological samples, grades them for the quantity of fat present, and the levels of inflammation and fibrosis. A score of 0 is considered completely healthy (devoid of any of these three characteristics), while a score of 8 indicates severe pathology, advanced as far as cirrhosis.
Time frame: Dec 2019
AST and ALT will be measured on the day when liver biopsy is collected
Time frame: Dec 2019
Liver fat and fibrosis will also be measured non-invasively via FibroScan TM
University of Missouri-Columbia
Other
Contribution of De Novo Lipogenesis in Severity of Nonalcoholic Fatty Liver Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04801849
Digestive System Diseases, Fatty Liver
La Jolla, California, United States
View Trial DetailsNCT05877547
Digestive System Diseases, Fatty Liver
Chandler, Arizona, United States
View Trial DetailsNCT05560607
Digestive System Diseases, Fatty Liver
San Antonio, Texas, United States
View Trial DetailsNCT04944992
Digestive System Diseases, Fatty Liver
Montclair, California, United States
View Trial Details